Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Epitope Mapping
Immunotherapy
Lymphocytes, Tumor-Infiltrating
Oncolytic Viruses
Vaccination
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
accepted:
20
05
2022
entrez:
19
7
2022
pubmed:
20
7
2022
medline:
22
7
2022
Statut:
ppublish
Résumé
Many solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic viruses (OVs), including reovirus type 3 Dearing, can enhance the efficacy of immunotherapy by recruiting CD8 We performed an in-depth characterization of the reovirus-induced T-cell response in immune-competent mice bearing pancreatic KPC3 tumors. The immunodominant CD8 Reovirus administration did not induce tumor-specific T cells but rather induced high frequencies of reovirus-specific CD8 These findings provide proof of concept that OV-specific T cells, despite not being tumor-specific, can be exploited as potent effector cells for anticancer treatment when primed before virotherapy. This is an attractive strategy for low-immunogenic tumors lacking tumor-specific T cells.
Sections du résumé
BACKGROUND
Many solid tumors do not respond to immunotherapy due to their immunologically cold tumor microenvironment (TME). We and others found that oncolytic viruses (OVs), including reovirus type 3 Dearing, can enhance the efficacy of immunotherapy by recruiting CD8
METHODS
We performed an in-depth characterization of the reovirus-induced T-cell response in immune-competent mice bearing pancreatic KPC3 tumors. The immunodominant CD8
RESULTS
Reovirus administration did not induce tumor-specific T cells but rather induced high frequencies of reovirus-specific CD8
CONCLUSIONS
These findings provide proof of concept that OV-specific T cells, despite not being tumor-specific, can be exploited as potent effector cells for anticancer treatment when primed before virotherapy. This is an attractive strategy for low-immunogenic tumors lacking tumor-specific T cells.
Identifiants
pubmed: 35853671
pii: jitc-2021-004464
doi: 10.1136/jitc-2021-004464
pmc: PMC9301813
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: CG, NvM, and TvH filed a patent (P335646NL) regarding the research described in this manuscript. All other authors declare no competing interests.
Références
J Virol. 1978 Nov;28(2):444-9
pubmed: 214572
Nature. 2006 Mar 23;440(7083):540-4
pubmed: 16525420
J Immunother Cancer. 2019 Feb 1;7(1):26
pubmed: 30709365
PLoS One. 2012;7(10):e48064
pubmed: 23110175
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33046622
Clin Cancer Res. 2014 Dec 1;20(23):5946-55
pubmed: 25294913
Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Front Immunol. 2019 May 09;10:1014
pubmed: 31143179
Virology. 1969 Dec;39(4):791-810
pubmed: 4311639
J Virol. 2005 Dec;79(23):14981-5
pubmed: 16282499
Sci Immunol. 2017 May 19;2(11):
pubmed: 28763795
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33082167
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298865
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142841
Cancer Gene Ther. 2022 Jun;29(6):793-802
pubmed: 34135475
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
Oncoimmunology. 2020 Jul 16;9(1):1794424
pubmed: 32923158
Nat Commun. 2020 Nov 9;11(1):5660
pubmed: 33168830
J Immunol. 2017 Apr 1;198(7):2979-2988
pubmed: 28202614
Control Clin Trials. 1990 Apr;11(2):116-28
pubmed: 2161310
Oncogene. 2005 Nov 21;24(52):7720-8
pubmed: 16299532
Mol Ther. 2015 Oct;23(10):1630-40
pubmed: 26112079
Nat Commun. 2020 Mar 13;11(1):1395
pubmed: 32170083
Nat Commun. 2019 Nov 28;10(1):5415
pubmed: 31780669
J Virol. 2018 Jul 31;92(16):
pubmed: 29875235
Clin Cancer Res. 2009 Jul 1;15(13):4374-4381
pubmed: 19509134
Nat Biotechnol. 2020 Apr;38(4):420-425
pubmed: 32042168
Int J Cancer. 2022 Feb 15;150(4):688-704
pubmed: 34716584
J Clin Microbiol. 2013 Sep;51(9):3047-54
pubmed: 23850952
Science. 2008 Nov 14;322(5904):1097-100
pubmed: 19008445
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799479
Nat Commun. 2019 Feb 4;10(1):567
pubmed: 30718505
Cancer Res. 2010 Mar 15;70(6):2435-44
pubmed: 20215509
J Immunol. 2000 Jul 15;165(2):869-77
pubmed: 10878361
Hum Gene Ther. 1996 Jan 20;7(2):215-22
pubmed: 8788172
Sci Transl Med. 2017 Sep 20;9(408):
pubmed: 28931654
Cancers (Basel). 2018 Jun 15;10(6):
pubmed: 29914097
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
Cancer Res. 2007 Mar 15;67(6):2840-8
pubmed: 17363607
Br J Cancer. 2019 Oct;121(8):647-658
pubmed: 31530903
J Proteome Res. 2019 Jun 7;18(6):2666-2675
pubmed: 31095916
Clin Cancer Res. 2020 Jan 1;26(1):71-81
pubmed: 31694832
Nature. 2002 Jan 31;415(6871):536-41
pubmed: 11823861
J Virol. 2020 Apr 16;94(9):
pubmed: 32102875
J Virol. 2000 Apr;74(8):3486-93
pubmed: 10729122
Eur J Immunol. 2018 Jan;48(1):120-127
pubmed: 28921501
Trends Immunol. 2020 May;41(5):406-420
pubmed: 32223932
Mol Cancer Ther. 2016 May;15(5):767-73
pubmed: 27197256
Nat Biotechnol. 2016 Oct;34(10):1037-1045
pubmed: 27571370
Cell Rep. 2018 Feb 6;22(6):1484-1495
pubmed: 29425504
J Exp Med. 1997 Jan 20;185(2):317-28
pubmed: 9016880
J Immunol. 2009 Jun 1;182(11):6682-9
pubmed: 19454662
Cancer Res. 1996 Jan 1;56(1):21-6
pubmed: 8548765